Table 1.

Patient characteristics at initiation of nivolumab and irinotecan treatments

Total	Nivolumab N=34	Irinotecan N=66	P value (Fisher's exact test)
Sex
Male	26 (76.5%)	53 (80.3%)	0.796
Female	8 (23.5%)	13 (19.7%)
Age
Median (range)	67 (51–84)	66 (41–77)
Performance status (PS)
PS 0	3 (8.8%)	9 (13.6%)	0.746
>1	31 (91.2%)	57 (86.4%)
Histological type
Intestinal	21 (61.8%)	37 (56.0%)	0.83
Diffuse	13 (38.2%)	26 (44.0%)
HER2 status
Negative	24 (80.0%)	34 (69.4%)	0.307
Positive	6 (20.0%)	15 (30.6%)
Disease status
Recurrent	18 (52.9%)	19 (28.8%)	0.0281
Stage IV	16 (47.1%)	47 (71.2%)
Peritoneal metastasis
Absent	16 (47.1%)	38 (57.6%)	0.398
Present	18 (52.9%)	28 (42.4%)
No of metastatic sites
1	4 (11.8%)	12 (18.2%)	0.285
≥2	30 (88.2%)	54 (81.8%)
No of prior chemotherapy lines
<3	10 (29.4%)	62 (93.9%)	<0.0001
≥3	24 (70.6%)	4 (6.1%)
Agents contained in prior chemotherapy
Fluoropyrimidine	34 (100%)	66 (100%)
Platinum	31 (91.2%)	60 (90.9%)	1.000
Taxane	33 (97.1%)	62 (93.9%)	0.659
Ramucirumab	13 (38.2%)	20 (30.3%)	0.502
Irinotecan	22 (64.7%)	0 (0%)
Immune check point inhibitor	0 (%)	1 (1.5%)
ALP (U/L)
<360	17 (50.0%)	38 (57.6%)	0.528
≥360	17 (50.0%)	28 (42.4%)

ALP, alkaline phosphatase.